TrialThe Lancet. Oncology2019

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.

Douglas H Brand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.